Cyclooxygenase-2 inhibitors and cardiovascular thromboembolic events

Cyclooxygenase-2 inhibitors and cardiovascular thromboembolic events.

iate discriminant analysis did not select V5 or V6 as leads in which ST-segment shift distinguished patients with acute LMCA obstruction from patients with acute obstruction of the left anterior descending coronary artery (LAD). Therefore, we do not consider ST-segment depression in leads V5 and V6 to be a characteristic finding in “LMCA AMI patients.” The findings of our patients indicated tha...

Risk of Cardiovascular Events and Cyclooxygenase-2 Inhibitors

Risk of cardiovascular events and cyclooxygenase-2 inhibitors Selective cyclooxygenase-2 (Cox-2) inhibitors have been at the centre of public attention since the revelation that the use of these drugs is associated with an increased risk of cardiovascular events (Tabrizchi 2005). Certainly pharmaco vigilance has an important place in the public domain and any new therapeutic information that le...

Cyclooxygenase-2 inhibition and cardiovascular events.

The Promise Introduction of selective cyclooxygenase (COX)-2 inhibitors held a promise of improved treatment of arthritis without the gastrointestinal effects associated with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), which effect both COX-1 and COX-2 activity. Celecoxib, etodolac, meloxicam, and rofecoxib are classified as selective COX-2 inhibitors. Initial placebo and l...

Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?

Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now.

Now Nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), including nonselective nonaspirin NSAIDs and cyclooxygenase-2 selective (COX-2) inhibitors, are widely used for various arthritides and pain syndromes. Cyclooxygenase-2 inhibitors in particular have been an enormous financial success, with more than $5 billion in sales in the United States in 2003 (1). That market took a huge hit rec...